Home | Contact | Sitemap | Santen Worldwide

Text Size

A
A
A

What's New

News Release

Sep 6, 2019 Sponsorship Agreement for IBSA Blind Football Asian Championships 2019 signed between Santen, IBF Foundation, and JBFA
Aug 30, 2019 Santen Announces Topline Pivotal Data for DE-128 (MicroShunt) Demonstrating Reductions in Intraocular Pressure and Medication Use in Patients
Aug 1, 2019 Santen Reports the 1st Quarter Fiscal 2019 Consolidated Performance
Jul 24, 2019 Notice on the Completion of Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Jul 3, 2019 Santen Included in All Four ESG Investment Indices Selected by GPIF
Jun 26, 2019 Corporate Social Responsibility (CSR) page on our website has been updated
Jun 26, 2019 Oxford Biomedica and Santen enter R&D collaboration and Option & Licence Agreement for development of gene therapy vectors for inherited retinal disea
Jun 25, 2019 Notice on the Disposal of Treasury Shares Under Restricted Stock-Linked Remuneration Program
Jun 11, 2019 Santen Chooses SAP S/4HANA Cloud and Other SAP Solutions to Reform Key Operation System and Strengthen Global Management Structure
May 9, 2019 Santen Reports Fiscal 2018 Consolidated Performance
May 9, 2019 Notice of Board of Director and Corporate Auditor Nominations
May 9, 2019 Notice of Board of Director and Corporate Auditor Nominations
May 9, 2019 Santen Reports Fiscal 2018 Consolidated Performance
Apr 26, 2019 Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States
Apr 26, 2019 Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States
Apr 18, 2019 Santen Announces Launch of LENTIS Comfort, Low-Add Segmental Intraocular Lens for Cataract Treatment in Japan
Apr 18, 2019 Santen Announces Launch of LENTIS Comfort, Low-Add Segmental Intraocular Lens for Cataract Treatment in Japan
Mar 27, 2019 Santen Announces Cancellation of Treasury Shares
Mar 27, 2019 Santen Announces Cancellation of Treasury Shares
Mar 25, 2019 Santen Announces Completion of Repurchase of Own Shares
Mar 25, 2019 Santen Announces Completion of Repurchase of Own Shares
Mar 13, 2019 Notice of Corporate Officer Appointments
Mar 13, 2019 Notice of Corporate Officer Appointments
Mar 8, 2019 Santen to Conduct Activities to Raise Disease Awareness during World Glaucoma Week, March 10 to 16
Mar 8, 2019 Santen to Conduct Activities to Raise Disease Awareness during World Glaucoma Week, March 10 to 16
Mar 6, 2019 Santen Selected and Launches Photo-Crosslinking Research and Development Project for Pathologic Myopia Treatment for CiCLE Program
Mar 6, 2019 Santen Selected and Launches Gene Therapy Drug Research and Development Project for Inherited Ocular Disease Treatment for CiCLE Program
Mar 6, 2019 Santen Selected and Launches Gene Therapy Drug Research and Development Project for Inherited Ocular Disease Treatment for CiCLE Program
Mar 6, 2019 Santen Selected and Launches Photo-Crosslinking Research and Development Project for Pathologic Myopia Treatment for CiCLE Program
Mar 1, 2019 Santen Announces Status of Repurchase of Own Shares
Mar 1, 2019 Santen Announces Status of Repurchase of Own Shares
Feb 20, 2019 Santen Announces Repurchase of Own Shares
Feb 20, 2019 Santen Announces Repurchase of Own Shares
Feb 5, 2019 Santen Reports the 3rd Quarter Fiscal 2018 Consolidated Performance
Jan 31, 2019 Santen Hosts Event to Raise Public Awareness of Importance of Continued Glaucoma Treatment Prior to Sponsoring World Glaucoma Week in March
Jan 25, 2019 Santen's Tampere manufacturing facility to be acquired by NextPharma
Jan 8, 2019 Santen Updates Pipeline in Corporate Presentation of January 8, 2019

Working at Advanced Vision Science